Paroxetine in the Treatment of Generalized Social Phobia
- 1 June 1996
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 16 (3) , 218-222
- https://doi.org/10.1097/00004714-199606000-00005
Abstract
We conducted an 11-week forced-escalation open-label study of paroxetine in the treatment of 36 patients with generalized social phobia. At the mean dosage of 47.9 +/- 6.2 mg/day, 23 of 30 completers (77%) were deemed responders on the basis of a clinician rating of either "very much improved" or "much improved" on the Clinical Global Impressions scale. Duke Social Phobia Scale ratings declined from 35.5 +/- 13.1 at baseline to 19.7 +/- 17.4 at week 11 (pKeywords
This publication has 24 references indexed in Scilit:
- Social Phobia in General Health Care: An Unrecognised Undertreated Disabling DisorderThe British Journal of Psychiatry, 1996
- The Boundary of Social PhobiaArchives of General Psychiatry, 1994
- Psychiatric Comorbidity in Hospitalized Adolescent Substance AbusersJournal of the American Academy of Child & Adolescent Psychiatry, 1994
- Alcoholism and phobic anxiety-a clinical-demographic comparisonAddiction, 1994
- Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxietyAmerican Journal of Psychiatry, 1994
- Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United StatesArchives of General Psychiatry, 1994
- Pharmacotherapy of Social PhobiaThe British Journal of Psychiatry, 1992
- Phenelzine vs Atenolol in Social PhobiaArchives of General Psychiatry, 1992
- Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitorEuropean Neuropsychopharmacology, 1992
- Cognitive-Behavioral and Pharmacological Treatments of Social PhobiaArchives of General Psychiatry, 1991